viewVerona Pharma

Verona Pharma has compound with 'massive potential to impact lives of COPD and asthma patients'

Verona Pharma PLC (LON:VRP) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years.

''When we started it was really three or four people, we didn't have a  lot of money, we had early data and over the last five years we've raised significant capital, hired some excellent people to supplement the team and delivered a number of different clinical trials which have shown we have a compound that has massive potential to impact the lives of patients with COPD as well as with asthma or cystic fibrosis.''

''I'm actually quite disappointed in the current share price''.

''I think there's a massive upside.''.

''Since I joined the company as chairman I've probably spent £300k buying shares - £125k of that this year to demonstrate my belief in the company and our programme''.

Quick facts: Verona Pharma

Price: 46 GBX

Market: AIM
Market Cap: £48.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...



Morning Report: Smiths Group halts planned demerger of medical arm

Headlines from the Proactive UK newsroom. Smiths Group (LON:SMIN) has halted the planned demerger of its medical arm due to the coronavirus crisis. Smiths Medical needs to concentrate on the delivery of ventilators and other critical care devices, though the intention remains to separate once...

on 31/3/20

2 min read